



Invitation to Business Update April 16th 2020

Oslo, April 14, 2020 – Vaccibody AS will host a webcast on April 16, 2020 at 1:00 PM (CET) to update on the business and present the results for FY19.

The presentation given by the Company's senior management team will be followed by a Q&A session in English. The Annual report will be released on Wednesday 15 April.

To participate in the webcast, please [register here](#)* or dial-in via the below numbers. Dial-in details:

Participant Passcode: 258751

Norway: +47 2140 3861

Sweden: +46 (0)8 1211 1105

Denmark: +45 78723185

UK: +44 (0)208 089 4223

USA: +1 334-777-6981

The presentation will be available on Vaccibody's website, www.vaccibody.com 12:00 PM (CET) April 16. The webcast replay will also be made available after the event.

*https://channel.royalcast.com/webcast/hegnarmedia/20200416_3/

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. Further, the Company focuses its research on infectious diseases.

Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody's vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody's vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. In addition, Vaccibody has collaborations with Roche and Nektar Therapeutics.

Vaccibody's lead product candidates are VB10.NEO, a personalized therapeutic cancer neoantigen vaccine currently being evaluated in a Phase I/IIa clinical trial, and VB10.16, a therapeutic cancer vaccine against HPV16-related cancers that is currently being tested in a Phase II clinical trial.

Vaccibody's shares are traded on NOTC, a marketplace for unlisted shares managed by NOTC AS, which is owned 100% by Oslo Børs ASA, the Oslo Stock Exchange.

Further information about the Company may be found at <http://www.vaccibody.com>

Contact:

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

mengsig@vaccibody.com

Vaccibody AS

Oslo Research Park

Gaustadalléen 21

0349 Oslo, Norway